UNSPSC 51294102: Nafenodone

This classification denotes an antidepressant agent with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O501R1CSQ, chemically known as 1(2h)-naphthalenone, 3,4-dihydro-2-(2-(dimethylamino)ethyl)-2-phenyl-, (s)- but generally known as nafenodone, which bears US NIH Compound Identifier 65834. European Medicines Agency schedules Nafenodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09119MIG.

UNSPSC 51294102 Nafenodone (Commodity) does not align with the state and local opportunities recently posted under this code. The three most recent solicitations—from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—involve naloxone, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products respectively. None of these procurements target nafenodone specifically. The code shows little relevant recent activity for the narrowly defined pharmaceutical product it nominally describes.

The geographic spread of recent pharmaceutical-related state and local procurement spans Florida, Texas, and Minnesota, with MMCAP's cooperative purchasing vehicle extending across multiple states including Oregon. Seminole County issued an IFB (Solicitation IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and quarterly deliveries to Sanford, Florida. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment programs. MMCAP issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Vendors responding to MMCAP must maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements. Given the mismatch between the code's nominal scope and actual procurement activity, firms pursuing this code should clarify whether their product portfolio aligns with the broader pharmaceutical distribution and benefit management work that state and local health and human services agencies are actually procuring.